Substance / Medication

Pretomanid

Overview

Active Ingredient
pretomanid
RxNorm CUI
2198359

Indications

Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This d

Labeler: Viatris Specialty LLCUpdated: 2024-11-15T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Pretomanid Tablets used in the combination regimen with bedaquiline and linezolid are contraindicated in patients for whom bedaquiline and/or linezolid are contraindicated. Refer to the bedaquiline and linezolid prescribing information.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Hepatic Safety of Bedaquiline, Delamanid, and Pretomanid: A Systematic Review and Meta-analysis.
Al Omar Mohamad Faisal Said, Alchikhsuliman Izz Eddin Majed, Awad Sondos Mahmoud et al. · Int J Mycobacteriol · 2025
PMID: 41411378Meta-Analysis
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review.
Silva Denise Rossato, Fernandes Flávia Fonseca, Ferreira Juliana Carvalho et al. · J Bras Pneumol · 2025
PMID: 39813501Meta-AnalysisFull text (PMC)
Pretomanid for tuberculosis: a systematic review.
Gils Tinne, Lynen Lutgarde, de Jong Bouke C et al. · Clin Microbiol Infect · 2022
PMID: 34400340Meta-Analysis
Long term outcomes in drug resistant tuberculosis with Bedaquiline, Pretomanid and varying doses of Linezolid.
Daniel Bella Devaleenal, Shanmugam Sivakumar, Mehta Rashi et al. · J Infect · 2025
PMID: 40381662RCTFull text (PMC)
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie Francesca, Bagdasaryan Tatevik R, Borisov Sergey et al. · N Engl J Med · 2022
PMID: 36053506RCTFull text (PMC)
Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling.
Zou Yuanxi, Nedelman Jerry, Lombardi Antonio et al. · Clin Pharmacokinet · 2022
PMID: 36180816RCTFull text (PMC)
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.
Tweed C D, Wills G H, Crook A M et al. · Int J Tuberc Lung Dis · 2021
PMID: 33762075RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pretomanid (substance)
SNOMED CT
789316005
UMLS CUI
C4310440
RxNorm CUI
2198359
Labeler
Viatris Specialty LLC

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.